IGF-1 LR3

IGF-1 LR3 (Insulin-like Growth Factor-1 Long Arg3) is a modified analog of endogenous IGF-1 engineered with two key changes: an arginine-3 substitution (replacing the native glutamate) and a 13 amino acid N-terminal extension. These modifications dramatically reduce binding affinity to IGF-binding proteins (IGFBPs 1–6), which normally act as transport and regulatory proteins for IGF-1 in circulation.

By reducing IGFBP binding, IGF-1 LR3 remains in its free, biologically active form significantly longer than native IGF-1, with an estimated half-life of 20–30 hours compared to ~12 minutes for native IGF-1. This extended activity makes it a powerful tool for studying the IGF-1 receptor (IGF-1R) signaling axis, cellular proliferation, differentiation, and anabolic metabolism in research settings.

• IGF-1 receptor (IGF-1R) signaling and AKT/mTOR pathway studies
• Protein synthesis, nitrogen retention, and anabolic metabolism research
• Reduced IGFBP binding and extended half-life pharmacokinetic research
• Cell proliferation, differentiation, and anti-apoptotic signaling
• Muscle satellite cell activation and myogenesis studies
• Comparison with native IGF-1 and IGF-1 DES(1-3) variants

Dose levels referenced by the MVLabs peptide calculator, shown for research reference only:

Long-acting IGF. Post-workout. Maximum dose 0.1 mg.

Research reference only — not dosing guidance for human use. Use the calculator for other vials or volumes.

Supplied as a lyophilized powder. Store at 2–8 °C on receipt; protect from heat, light and moisture, and avoid excessive agitation. If reconstitution is required for laboratory work, use sterile technique — bacteriostatic water, or 0.6% acetic acid for low-solubility peptides. Protocols vary by research application.